EYENEYENOVIA, INC.

Nasdaq eyenovia.com


$ 0.99 $ 0.07 (7.74 %)    

Friday, 03-May-2024 15:59:55 EDT
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 1.01
$ 1.00
$ 0.00 x 0
$ 1.01 x 1,100
$ 0.97 - $ 1.14
$ 0.50 - $ 5.79
2,484,767
na
41.44M
$ 1.22
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-18-2024 12-31-2023 10-K
2 11-13-2023 09-30-2023 10-Q
3 08-11-2023 06-30-2023 10-Q
4 05-12-2023 03-31-2023 10-Q
5 03-31-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-11-2022 06-30-2022 10-Q
8 05-13-2022 03-31-2022 10-Q
9 03-30-2022 12-31-2021 10-K
10 11-12-2021 09-30-2021 10-Q
11 08-12-2021 06-30-2021 10-Q
12 05-14-2021 03-31-2021 10-Q
13 03-30-2021 12-31-2020 10-K
14 11-12-2020 09-30-2020 10-Q
15 08-14-2020 06-30-2020 10-Q
16 05-14-2020 03-31-2020 10-Q
17 03-30-2020 12-31-2019 10-K
18 11-13-2019 09-30-2019 10-Q
19 08-13-2019 06-30-2019 10-Q
20 05-14-2019 03-31-2019 10-Q
21 03-27-2019 12-31-2018 10-K
22 11-13-2018 09-30-2018 10-Q
23 08-14-2018 06-30-2018 10-Q
24 05-09-2018 03-31-2018 10-Q
25 04-02-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 eyenovia-provides-clinical-and-scientific-update-on-fda-approved-products-mydcombi-and-clobetasol-propionate-ophthalmic-suspension

Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest ...

 eyenovia-initiates-process-to-explore-strategic-alternatives-to-maximize-shareholder-value

The company announced its plans for accelerating development of its potential multi-billion dollar product for pediatric progre...

 over-2m-bet-on-nextnav-check-out-these-3-penny-stocks-insiders-are-aggressively-buying

The Dow Jones index closed higher by over 400 points on Wednesday. When insiders purchase or sell shares, it indicates their co...

 hc-wainwright--co-reiterates-buy-on-eyenovia-maintains-12-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates Eyenovia (NASDAQ:EYEN) with a Buy and maintains $12 price target.

 recap-eyenovia-q4-earnings
Recap: Eyenovia Q4 Earnings
03/18/2024 20:30:15

 eyenovia-q4-eps-018-misses-017-estimate-sales-259k-miss-13000k-estimate

Eyenovia (NASDAQ:EYEN) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.17) by...

 earnings-scheduled-for-march-18-2024

Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to report earnings for its fourth quarter.

 earnings-preview-for-eyenovia
Earnings Preview For Eyenovia
03/15/2024 15:01:00

 hc-wainwright--co-reiterates-buy-on-eyenovia-maintains-12-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates Eyenovia (NASDAQ:EYEN) with a Buy and maintains $12 price target.

 why-sophia-genetics-shares-are-trading-lower-by-19-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expect...

 beyond-cataract-surgery-analyst-highlights-broader-market-potential-for-eyenoviaformosas-steroid-for-post-eye-surgery-pain-inflammation

FDA-approved clobetasol propionate ophthalmic suspension 0.05% (APP13007) by Formosa Pharma & AimMax. Breakthrough post-ocu...

 formosa-and-aimmax-therapeutics-secure-fda-approval-for-clobetasol-propionate-ophthalmic-suspension-005-for-treatment-of-post-operative-inflammation-and-pain-following-ocular-surgery

"With FDA approval now secured, we look forward to working with our U.S. commercialization partner, Eyenovia, Inc., to reac...

 eyenovia-re-acquires-development-and-commercialization-rights-to-micropine-in-the-us-and-canada-to-pay-bausch--lomb-ireland-limited-an-upfront-payment-consisting-of-2m-in-cash-and-3m-in-shares

 Eyenovia, Inc. (NASDAQ:EYEN), a commercial-stage, ophthalmic company, today announced that it has re-acquired the rights to Mi...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION